Dr Joao Pedro Ferreira

All Stories

1. 
   Pathophysiological Sex Differences in Heart Failure Progression After Acute Coronary Syndrome: Insights From the EXAMINE Trial

   Article • Journal of Cardiac Failure, June 2024, Elsevier

   Dr Joao Pedro Ferreira

2. 
   High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT

   Article • International Journal of Cardiology, May 2024, Elsevier

   Dr Joao Pedro Ferreira

3. 
   Heart Failure in Brazil and the Need to Measure and Take Action

   Article • Journal of Cardiac Failure, May 2024, Elsevier

   Dr Joao Pedro Ferreira

4. 
   conTemporary reflectiOns regarding heart failure manaGEmenT – How to ovERcome the PorTuguese barriers (TOGETHER-PT)

   Article • Revista Portuguesa de Cardiologia, May 2024, Elsevier

   Dr Joao Pedro Ferreira

5. 
   High Risk of Stroke in Patients With Worsening Heart Failure, Reduced Ejection Fraction, Coronary Heart Disease and Sinus Rhythm: Risk Prediction Score Analysis From the COMMANDER-HF Trial

   Article • Journal of Cardiac Failure, April 2024, Elsevier

   Professor John GF Cleland, Dr Joao Pedro Ferreira

6. 
   Is Reducing Heart Failure Hospitalization Associated With Reducing Mortality in Heart Failure Trials?

   Article • JACC Heart Failure, April 2024, Elsevier

   Dr Joao Pedro Ferreira

7. 
   Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR‐Preserved analysis

   Article • European Journal of Heart Failure, March 2024, Wiley

   Dr Joao Pedro Ferreira

8. 
   Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme

   Article • European Journal of Heart Failure, March 2024, Wiley

   Dr Joao Pedro Ferreira

9. 
   Home- versus centre-based EXercise InTervention in patients with Heart Failure (EXIT-HF trial): A pragmatic randomized controlled trial

   Article • Revista Portuguesa de Cardiologia, March 2024, Elsevier

   Fernando Ribeiro, Dr Joao Pedro Ferreira

10. 
    Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: Findings from the MESA study

    Article • Atherosclerosis, March 2024, Elsevier

    Dr Joao Pedro Ferreira

11. 
    Semaglutide and Cardiovascular Outcomes

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, February 2024, New England Journal of Medicine (NEJM/MMS)

    Dr Joao Pedro Ferreira

12. 
    Cardiovascular Prevention in Obese Patients Without Diabetes: Risk-based Strategies Are Needed

    Article • Journal of Cardiac Failure, February 2024, Elsevier

    Dr Joao Pedro Ferreira

13. 
    Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Preserved

    Article • European Journal of Heart Failure, January 2024, Wiley

    Dr Joao Pedro Ferreira

14. 
    Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF

    Article • JACC Heart Failure, January 2024, Elsevier

    Dr Joao Pedro Ferreira

15. 
    Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR‐Preserved

    Article • Journal of Cachexia Sarcopenia and Muscle, December 2023, Wiley

    Dr Joao Pedro Ferreira

16. 
    Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trials

    Article • European Journal of Heart Failure, December 2023, Wiley

    Dr Joao Pedro Ferreira

17. 
    Mineralocorticoid receptor antagonist indication and underuse in high‐risk post‐myocardial infarction patients

    Article • European Journal of Heart Failure, December 2023, Wiley

    Dr Joao Pedro Ferreira

18. 
    Risk of readmission and death after hospitalization for worsening heart failure: Role of post‐discharge follow‐up visits in a real‐world study from the Grand Est Region of France

    Article • European Journal of Heart Failure, December 2023, Wiley

    Dr Joao Pedro Ferreira

19. 
    Growth differentiation factor‐15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program

    Article • European Journal of Heart Failure, November 2023, Wiley

    Dr Joao Pedro Ferreira

20. 
    Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial

    Article • ESC Heart Failure, November 2023, Wiley

    Dr Pierpaolo Pellicori, Professor John GF Cleland, Dr Joao Pedro Ferreira

21. 
    Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial

    Article • Journal of Cardiac Failure, October 2023, Elsevier

    Dr Joao Pedro Ferreira

22. 
    Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure

    Article • Circulation, September 2023, Wolters Kluwer Health

    Dr Joao Pedro Ferreira

23. 
    Missed opportunities in the diagnosis of heart failure: a real‐world assessment

    Article • ESC Heart Failure, September 2023, Wiley

    Dr Joao Pedro Ferreira

24. 
    Changes in health-related quality of life and treatment effects in chronic heart failure: a meta-analysis

    Article • International Journal of Cardiology, September 2023, Elsevier

    Dr Joao Pedro Ferreira

25. 
    Response to Letter to Editor From Banerjee et al: “Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure”

    Article • The Journal of Clinical Endocrinology & Metabolism, August 2023, Endocrine Society

    Dr Joao Pedro Ferreira

26. 
    Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium–glucose cotransporter 2 inhibitors

    Article • European Journal of Heart Failure, August 2023, Wiley

    Dr Joao Pedro Ferreira

27. 
    Role of aldosterone in mid‐ and long‐term left ventricular remodelling after acute myocardial infarction: The REMI study

    Article • European Journal of Heart Failure, August 2023, Wiley

    Dr Joao Pedro Ferreira

28. 
    Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE

    Article • European Journal of Heart Failure, August 2023, Wiley

    Dr Joao Pedro Ferreira

29. 
    GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes

    Article • Journal of the American College of Cardiology, August 2023, Elsevier

    DAVIDE CARVALHO, Dr Joao Pedro Ferreira

30. 
    Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF

    Article • BMJ Open, August 2023, BMJ

    Professor John GF Cleland, Dr Joao Pedro Ferreira

31. 
    Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS‐HF trial

    Article • European Journal of Heart Failure, July 2023, Wiley

    Dr Joao Pedro Ferreira

32. 
    Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure

    Article • The Journal of Clinical Endocrinology & Metabolism, July 2023, Endocrine Society

    Dr Joao Pedro Ferreira

33. 
    Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction

    Article • JAMA Cardiology, July 2023, American Medical Association (AMA)

    Dr Joao Pedro Ferreira

34. 
    Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled

    Article • Arteriosclerosis Thrombosis and Vascular Biology, July 2023, Wolters Kluwer Health

    Dr Joao Pedro Ferreira

35. 
    High- versus low-dose losartan and uric acid: An analysis from HEAAL

    Article • Journal of Cardiology, July 2023, Elsevier

    Dr Joao Pedro Ferreira

36. 
    Increased Risk of Heart Failure Hospitalization With GLP-1 Receptor Agonists in Patients With Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT Trials

    Article • Journal of Cardiac Failure, July 2023, Elsevier

    Dr Joao Pedro Ferreira

37. 
    Association between a hospitalization for heart failure and the initiation/discontinuation of guideline‐recommended treatments: An analysis from the Swedish Heart Failure Registry

    Article • European Journal of Heart Failure, June 2023, Wiley

    Dr Joao Pedro Ferreira

38. 
    Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR‐Preserved trial

    Article • European Journal of Heart Failure, June 2023, Wiley

    Dr Joao Pedro Ferreira

39. 
    Lung ultrasound and diuretic therapy in chronic heart failure: a randomised trial

    Article • Clinical Research in Cardiology, June 2023, Springer Science + Business Media

    Dr Joao Pedro Ferreira

40. 
    Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin

    Article • JACC Heart Failure, June 2023, Elsevier

    Dr Joao Pedro Ferreira

41. 
    Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation

    Article • European Journal of Heart Failure, May 2023, Wiley

    Dr Joao Pedro Ferreira

42. 
    Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR‐Preserved trial

    Article • European Journal of Heart Failure, May 2023, Wiley

    Dr Joao Pedro Ferreira

43. 
    Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study

    Article • Circulation Heart Failure, May 2023, Wolters Kluwer Health

    Dr Pierpaolo Pellicori, Professor John GF Cleland, Dr Joao Pedro Ferreira

44. 
    Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories

    Article • Journal of the American College of Cardiology, May 2023, Elsevier

    Dr Joao Pedro Ferreira

45. 
    Interaction of natriuretic peptide levels and ejection fraction on outcomes with dapagliflozin and empagliflozin in heart failure

    Article • European Journal of Heart Failure, May 2023, Wiley

    Dr Joao Pedro Ferreira

46. 
    A machine learning‐derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: findings from the HOMAGE trial

    Article • European Journal of Heart Failure, April 2023, Wiley

    Dr Pierpaolo Pellicori, Professor John GF Cleland, Dr Joao Pedro Ferreira

47. 
    Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM‐HF and ATMOSPHERE

    Article • European Journal of Heart Failure, April 2023, Wiley

    Dr Joao Pedro Ferreira

48. 
    The win ratio method in heart failure trials: lessons learnt from EMPULSE

    Article • European Journal of Heart Failure, April 2023, Wiley

    Dr Joao Pedro Ferreira

49. 
    Unsupervised clustering to differentiate rheumatoid arthritis patients based on proteomic signatures

    Article • Scandinavian Journal of Rheumatology, April 2023, Taylor & Francis

    Dr Joao Pedro Ferreira

50. 
    Urinary Proteomic Signature of Mineralocorticoid Receptor Antagonism by Spironolactone: Evidence from the Randomized-Controlled HOMAGE and PRIORITY Trials

    Article • April 2023, Cold Spring Harbor Laboratory Press

    Dr Pierpaolo Pellicori, Professor John GF Cleland, Dr Joao Pedro Ferreira

51. 
    Health status across major subgroups of patients with heart failure and preserved ejection fraction

    Article • European Journal of Heart Failure, April 2023, Wiley

    Dr Joao Pedro Ferreira

52. 
    Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials

    Article • International Journal of Cardiology, April 2023, Elsevier

    Dr Pierpaolo Pellicori, Professor John GF Cleland, Dr Joao Pedro Ferreira

53. 
    Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial

    Article • JACC Heart Failure, April 2023, Elsevier

    Dr Joao Pedro Ferreira

54. 
    Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial)

    Article • The American Journal of Cardiology, March 2023, Elsevier

    Dr Pierpaolo Pellicori, Professor John GF Cleland, Dr Joao Pedro Ferreira

55. 
    Effect of eplerenone on clinical stability of Japanese patients with acute heart failure

    Article • International Journal of Cardiology, March 2023, Elsevier

    Dr Joao Pedro Ferreira

56. 
    Investigação Clínica da Iniciativa do Investigador em Portugal: Identificação de Problemas e Propostas para Melhoria

    Article • Acta Médica Portuguesa, February 2023, Ordem dos Medicos

    Dr Joao Pedro Ferreira

57. 
    Glucagon‐like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta‐analysis of randomized placebo‐controlled outcome trials

    Article • Diabetes Obesity and Metabolism, February 2023, Wiley

    DAVIDE CARVALHO, Dr Joao Pedro Ferreira

58. 
    Door-to-furosemide time and clinical outcomes in acute heart failure

    Article • European Journal of Emergency Medicine, February 2023, Wolters Kluwer Health

    Dr Joao Pedro Ferreira

59. 
    Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled

    Article • Circulation, January 2023, Wolters Kluwer Health

    Dr Joao Pedro Ferreira

60. 
    Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause

    Article • Journal of the American Heart Association, January 2023, Wolters Kluwer Health

    Dr Joao Pedro Ferreira

61. 
    A 4-Variable Model to Predict Cardio-Kidney Events and Mortality in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort (CRIC) Study

    Article • American Journal of Nephrology, January 2023, Karger Publishers

    Miguel Bigotte Vieira, Dr Joao Pedro Ferreira

62. 
    Clinical and Pathophysiologic Insights of Free triiodothyronine/Free thyroxine Ratio in Patients with Heart Failure with Preserved Ejection Fraction: Data from the NETDiamond Cohort

    Article • Cardiology, January 2023, Karger Publishers

    Dr Joao Pedro Ferreira

63. 
    High- Versus Low-dose Losartan and Serum Potassium: An Analysis From HEAAL

    Article • Journal of Cardiac Failure, January 2023, Elsevier

    Dr Joao Pedro Ferreira

64. 
    Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial

    Article • European Heart Journal, December 2022, Oxford University Press (OUP)

    Dr Joao Pedro Ferreira

65. 
    Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

    Article • Nature Medicine, December 2022, Springer Science + Business Media

    Dr Joao Pedro Ferreira

66. 
    Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

    Article • The Lancet Infectious Diseases, December 2022, Elsevier

    Dr Joao Pedro Ferreira

67. 
    Interleukin-6, infection and cardiovascular outcomes in acute heart failure: Findings from the EDIFICA registry

    Article • Cytokine, December 2022, Elsevier

    Dr Joao Pedro Ferreira

68. 
    Impact of disease duration on proteomic bioprofile and prognosis in rheumatoid arthritis patients

    Article • Clinical and Experimental Rheumatology, November 2022, Clinical and Experimental Rheumatology

    Dr Joao Pedro Ferreira

69. 
    Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced

    Article • European Journal of Heart Failure, November 2022, Wiley

    Dr Joao Pedro Ferreira

70. 
    Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials

    Article • European Journal of Heart Failure, November 2022, Wiley

    Dr Pierpaolo Pellicori, Dr Joao Pedro Ferreira

71. 
    Clinical associations and prognostic implications of 6-minute walk test in rheumatoid arthritis

    Article • Scientific Reports, November 2022, Springer Science + Business Media

    Dr Joao Pedro Ferreira

72. 
    Steroidal MRA Across the Spectrum of Renal Function

    Article • JACC Heart Failure, November 2022, Elsevier

    Dr Joao Pedro Ferreira

73. 
    Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure

    Article • JAMA Cardiology, November 2022, American Medical Association (AMA)

    Dr Joao Pedro Ferreira

74. 
    Inductive database to support iterative data mining: Application to biomarker analysis on patient data in the Fight-HF project

    Article • Journal of Biomedical Informatics, November 2022, Elsevier

    Dr Joao Pedro Ferreira

75. 
    Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial

    Article • Clinical Research in Cardiology, October 2022, Springer Science + Business Media

    Dr Pierpaolo Pellicori, Dr Joao Pedro Ferreira

76. 
    Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial

    Article • European Heart Journal, October 2022, Oxford University Press (OUP)

    Dr Joao Pedro Ferreira

77. 
    Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: A secondary analysis of EMPEROR‐Reduced

    Article • European Journal of Heart Failure, October 2022, Wiley

    Dr Joao Pedro Ferreira

78. 
    Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction

    Article • Circulation, October 2022, Wolters Kluwer Health

    Dr Joao Pedro Ferreira

79. 
    Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction

    Article • Circulation Heart Failure, October 2022, Wolters Kluwer Health

    Dr Joao Pedro Ferreira

80. 
    Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR‐Preserved trial

    Article • European Journal of Heart Failure, October 2022, Wiley

    Dr Joao Pedro Ferreira

81. 
    Relaxin-2, pathophysiological insights and outcomes in heart failure with preserved ejection fraction: Findings from the NETDiamond cohort

    Article • International Journal of Cardiology, October 2022, Elsevier

    Dr Joao Pedro Ferreira

82. 
    External validation and extension of the TIMI risk score for heart failure in diabetes for patients with recent acute coronary syndrome: An analysis of the EXAMINE trial

    Article • Diabetes Obesity and Metabolism, September 2022, Wiley

    Dr Joao Pedro Ferreira

83. 
    Glucagon‐like peptide 1 receptor agonists in heart failure: the need for a rewind

    Article • European Journal of Heart Failure, September 2022, Wiley

    Dr Joao Pedro Ferreira

84. 
    Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial

    Article • European Journal of Heart Failure, September 2022, Wiley

    Dr Joao Pedro Ferreira

85. 
    Letter regarding the article ‘Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post‐hoc analysis from the REWIND randomized trial

    Article • European Journal of Heart Failure, September 2022, Wiley

    Dr Joao Pedro Ferreira

86. 
    Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial

    Article • Diabetes Obesity and Metabolism, September 2022, Wiley

    DAVIDE CARVALHO, Dr Joao Pedro Ferreira

87. 
    Clinical and pathophysiologic insights of FT3/FT4 ratio in patients with Heart Failure with Preserved Ejection Fraction: data from the NETDiamond cohort

    Article • September 2022, Springer Science + Business Media

    Dr Joao Pedro Ferreira

88. 
    Albiglutide in patients with type 2 diabetes and heart failure: a post‐hoc analysis from Harmony Outcomes

    Article • European Journal of Heart Failure, September 2022, Wiley

    DAVIDE CARVALHO, Dr Joao Pedro Ferreira

89. 
    Dyskalemia in people at increased risk for heart failure: findings from the heart ‘OMics’ in AGEing (HOMAGE) trial

    Article • ESC Heart Failure, September 2022, Wiley

    Dr Pierpaolo Pellicori, Dr Joao Pedro Ferreira

90. 
    Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure

    Article • European Journal of Heart Failure, August 2022, Wiley

    Dr Joao Pedro Ferreira

91. 
    Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes

    Article • Circulation, August 2022, Wolters Kluwer Health

    Dr Joao Pedro Ferreira

92. 
    Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme

    Article • European Heart Journal, August 2022, Oxford University Press (OUP)

    Dr Joao Pedro Ferreira

93. 
    Use of sodium glucose co‐transporter 2 inhibitors in acute heart failure: a practical guidance

    Article • ESC Heart Failure, August 2022, Wiley

    Dr Joao Pedro Ferreira

94. 
    Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial

    Article • Circulation, July 2022, Wolters Kluwer Health

    Dr Joao Pedro Ferreira

95. 
    Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial

    Article • European Journal of Heart Failure, July 2022, Wiley

    Dr Joao Pedro Ferreira

96. 
    Within trial comparison of survival time projections from short‐term follow‐up with long‐term follow‐up findings

    Article • ESC Heart Failure, July 2022, Wiley

    Dr Joao Pedro Ferreira

97. 
    Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Reduced

    Article • European Journal of Heart Failure, July 2022, Wiley

    Dr Joao Pedro Ferreira

98. 
    The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial

    Article • European Journal of Heart Failure, July 2022, Wiley

    Dr Pierpaolo Pellicori, Dr Joao Pedro Ferreira

99. 
    Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial

    Article • European Heart Journal, July 2022, Oxford University Press (OUP)

    Dr Joao Pedro Ferreira

100. 
     Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age

     Article • Journal of the American College of Cardiology, July 2022, Elsevier

     Dr Joao Pedro Ferreira

101. 
     Prognostic Implications of N-Terminal Pro–B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved

     Article • JACC Heart Failure, July 2022, Elsevier

     Dr Joao Pedro Ferreira

102. 
     Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled

     Article • European Heart Journal, June 2022, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

103. 
     Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER‐like endpoint definitions

     Article • European Journal of Heart Failure, June 2022, Wiley

     Dr Joao Pedro Ferreira

104. 
     Letter of reply to the letter by Ryan

     Article • Diabetes Obesity and Metabolism, May 2022, Wiley

     Dr Joao Pedro Ferreira

105. 
     Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta‐Analysis

     Article • Journal of the American Heart Association, May 2022, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

106. 
     Effect of glucagon‐like peptide‐1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta‐analysis of placebo‐controlled randomized trials

     Article • Diabetes Obesity and Metabolism, May 2022, Wiley

     Dr Joao Pedro Ferreira

107. 
     Weak Association Between Genetic Markers of Hyperuricemia and Cardiorenal Outcomes: Insights From the STANISLAS Study Cohort With a 20‐Year Follow‐Up

     Article • Journal of the American Heart Association, May 2022, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

108. 
     A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19

     Article • American Heart Journal, May 2022, Elsevier

     Dr Joao Pedro Ferreira

109. 
     Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization

     Article • Circulation, April 2022, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

110. 
     Sex differences in circulating proteins of patients with rheumatoid arthritis: A cohort study

     Article • International Journal of Rheumatic Diseases, April 2022, Wiley

     Dr Joao Pedro Ferreira

111. 
     Impact of smoking on cardiovascular risk and premature ageing: Findings from the STANISLAS cohort

     Article • Atherosclerosis, April 2022, Elsevier

     Dr Joao Pedro Ferreira

112. 
     Cardiac structure and function and quality of life associations in HFpEF: An analysis from TOPCAT-Americas

     Article • International Journal of Cardiology, April 2022, Elsevier

     Dr Joao Pedro Ferreira

113. 
     Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD

     Article • Diabetes Care, March 2022, American Diabetes Association

     Dr Joao Pedro Ferreira

114. 
     Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?

     Article • The Journal of Clinical Endocrinology & Metabolism, March 2022, Endocrine Society

     Dr Joao Pedro Ferreira

115. 
     Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure

     Article • European Journal of Heart Failure, March 2022, Wiley

     Dr Joao Pedro Ferreira

116. 
     Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial

     Article • European Journal of Heart Failure, March 2022, Wiley

     Dr Pierpaolo Pellicori, Dr Joao Pedro Ferreira

117. 
     Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction

     Article • Journal of the American College of Cardiology, March 2022, Elsevier

     Dr Joao Pedro Ferreira

118. 
     The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

     Article • Nature Medicine, February 2022, Springer Science + Business Media

     Dr Joao Pedro Ferreira

119. 
     Machine Learning-Derived Echocardiographic Phenotypes Predict Heart Failure Incidence in Asymptomatic Individuals

     Article • JACC Cardiovascular Imaging, February 2022, Elsevier

     Dr Joao Pedro Ferreira

120. 
     Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

     Article • Circulation, January 2022, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

121. 
     Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR‐Preserved trial

     Article • European Journal of Heart Failure, January 2022, Wiley

     Dr Joao Pedro Ferreira

122. 
     Prognostic relevance of magnesium alterations in patients with a myocardial infarction and left ventricular dysfunction: insights from the EPHESUS trial

     Article • European Heart Journal Acute Cardiovascular Care, January 2022, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

123. 
     Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced

     Article • European Journal of Heart Failure, January 2022, Wiley

     Dr Joao Pedro Ferreira

124. 
     Metabolic Syndrome and the Risk of Preclinical Heart Failure: Insights after 17 Years of Follow-Up from the STANISLAS Cohort

     Article • Cardiology, January 2022, Karger Publishers

     Dr Joao Pedro Ferreira

125. 
     Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

     Article • The Lancet Diabetes & Endocrinology, January 2022, Elsevier

     Dr Joao Pedro Ferreira

126. 
     Biomarker‐based assessment of collagen cross‐linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

     Article • European Journal of Heart Failure, December 2021, Wiley

     Dr Pierpaolo Pellicori, Dr Joao Pedro Ferreira

127. 
     Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction

     Article • European Heart Journal, December 2021, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

128. 
     The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial

     Article • Journal of Cardiac Failure, December 2021, Elsevier

     Dr Pierpaolo Pellicori, Dr Joao Pedro Ferreira

129. 
     Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT

     Article • European Journal of Heart Failure, November 2021, Wiley

     Dr Joao Pedro Ferreira

130. 
     Circulating Biomarkers and Cardiac Structure and Function in Rheumatoid Arthritis

     Article • Frontiers in Cardiovascular Medicine, November 2021, Frontiers

     Dr Joao Pedro Ferreira

131. 
     Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI

     Article • European Heart Journal, November 2021, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

132. 
     Weight changes in heart failure with preserved ejection fraction: findings from TOPCAT

     Article • Clinical Research in Cardiology, November 2021, Springer Science + Business Media

     Dr Joao Pedro Ferreira

133. 
     Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction

     Article • JAMA Cardiology, November 2021, American Medical Association (AMA)

     Dr Joao Pedro Ferreira

134. 
     Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations

     Article • European Heart Journal, October 2021, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

135. 
     Obituary: Paulo Bettencourt 1965–2021

     Article • European Journal of Heart Failure, October 2021, Wiley

     Dr Joao Pedro Ferreira

136. 
     Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial

     Article • Circulation, October 2021, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

137. 
     Empagliflozin and Major Renal Outcomes in Heart Failure

     Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, October 2021, New England Journal of Medicine (NEJM/MMS)

     Dr Joao Pedro Ferreira

138. 
     Empagliflozin in Heart Failure with a Preserved Ejection Fraction

     Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, October 2021, New England Journal of Medicine (NEJM/MMS)

     Dr Joao Pedro Ferreira

139. 
     Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS‐HF and RALES

     Article • European Journal of Heart Failure, October 2021, Wiley

     Dr Joao Pedro Ferreira

140. 
     Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial

     Article • Diabetes Obesity and Metabolism, October 2021, Wiley

     Dr Joao Pedro Ferreira

141. 
     Isolated diastolic hypertension and target organ damage: Findings from the STANISLAS cohort

     Article • Clinical Cardiology, September 2021, Wiley

     Dr Joao Pedro Ferreira

142. 
     Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial

     Article • Cardiovascular Diabetology, September 2021, Springer Science + Business Media

     Dr Joao Pedro Ferreira

143. 
     Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design

     Article • Diabetes & Metabolism, September 2021, Elsevier

     Dr Pierpaolo Pellicori, Dr Joao Pedro Ferreira

144. 
     Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure

     Article • Journal of the American College of Cardiology, September 2021, Elsevier

     Dr Joao Pedro Ferreira

145. 
     Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial

     Article • Journal of the American College of Cardiology, September 2021, Elsevier

     Dr Joao Pedro Ferreira

146. 
     Cardiac Remodeling and Diastolic Dysfunction in Paroxysmal Atrial Fibrillation

     Article • Journal of Clinical Medicine, August 2021, MDPI AG

     Dr Joao Pedro Ferreira

147. 
     Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial

     Article • European Journal of Heart Failure, August 2021, Wiley

     Dr Joao Pedro Ferreira

148. 
     Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial

     Article • European Heart Journal, August 2021, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

149. 
     Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial

     Article • Cardiovascular Diabetology, August 2021, Springer Science + Business Media

     Professor John GF Cleland, Dr Pierpaolo Pellicori, Dr Joao Pedro Ferreira

150. 
     Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF

     Article • Cardiovascular Research, July 2021, Oxford University Press (OUP)

     Professor John GF Cleland, Dr Joao Pedro Ferreira

151. 
     6-Minute Walking Test in Rheumatoid Arthritis: Clinical Associations and Prognostic Implications

     Article • July 2021, Springer Science + Business Media

     Dr Joao Pedro Ferreira

152. 
     Interplay between worsening kidney function and cardiovascular events in patients with type 2 diabetes: an analysis from the ACCORD trial

     Article • BMJ Open Diabetes Research & Care, July 2021, BMJ

     Dr Joao Pedro Ferreira

153. 
     Omecamtiv Mecarbil

     Article • Journal of the American College of Cardiology, July 2021, Elsevier

     Dr Joao Pedro Ferreira

154. 
     Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial

     Article • European Heart Journal, June 2021, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

155. 
     Identification of sex‐specific biomarkers predicting new‐onset heart failure

     Article • ESC Heart Failure, June 2021, Wiley

     Professor John GF Cleland, Dr Joao Pedro Ferreira

156. 
     Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR‐Reduced trial

     Article • European Journal of Heart Failure, June 2021, Wiley

     Dr Joao Pedro Ferreira

157. 
     Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial

     Article • European Journal of Heart Failure, June 2021, Wiley

     Dr Joao Pedro Ferreira

158. 
     Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension

     Article • Journal of Hypertension, June 2021, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

159. 
     New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial

     Article • Clinical Research in Cardiology, June 2021, Springer Science + Business Media

     Professor John GF Cleland, Dr Joao Pedro Ferreira

160. 
     Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial

     Article • Circulation Heart Failure, June 2021, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

161. 
     Serum microRNAs and antifibrotic response to eplerenone in acute myocardial infarction complicated by systolic dysfunction

     Article • International Journal of Cardiology, June 2021, Elsevier

     Dr Joao Pedro Ferreira

162. 
     Sodium-glucose co-transporter inhibitors in insulin-treated diabetes: a meta-analysis

     Article • European Journal of Endocrinology, June 2021, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

163. 
     Circulating levels of procollagen type I carboxy‐terminal propeptide reflect myocardial fibrosis

     Article • European Journal of Heart Failure, May 2021, Wiley

     Dr Joao Pedro Ferreira

164. 
     Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure

     Article • Clinical Cardiology, May 2021, Wiley

     Dr Joao Pedro Ferreira

165. 
     The Future of Meat: Health Impact Assessment with Randomized Evidence

     Article • The American Journal of Medicine, May 2021, Elsevier

     Dr Joao Pedro Ferreira

166. 
     Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome

     Article • Clinical Research in Cardiology, April 2021, Springer Science + Business Media

     Dr Joao Pedro Ferreira

167. 
     Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHESUS trial

     Article • Clinical Research in Cardiology, April 2021, Springer Science + Business Media

     Dr Joao Pedro Ferreira

168. 
     Cognitive function assessment for personalized heart failure disease management programmes

     Article • European Journal of Heart Failure, April 2021, Wiley

     Dr Joao Pedro Ferreira

169. 
     Blood pressure reduction and anti‐hypertensive treatment choice: A post‐hoc analysis of the SPRINT trial

     Article • Clinical Cardiology, April 2021, Wiley

     Dr Joao Pedro Ferreira

170. 
     Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial

     Article • Journal of the American Heart Association, April 2021, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

171. 
     Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial

     Article • European Heart Journal - Cardiovascular Pharmacotherapy, April 2021, Oxford University Press (OUP)

     Dr Pierpaolo Pellicori, Dr Joao Pedro Ferreira

172. 
     Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF

     Article • JACC Heart Failure, April 2021, Elsevier

     Professor John GF Cleland, Dr Pierpaolo Pellicori, Dr Joao Pedro Ferreira

173. 
     Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire

     Article • European Journal of Heart Failure, April 2021, Wiley

     Dr Joao Pedro Ferreira

174. 
     Red cell distribution width in patients with diabetes and myocardial infarction: An analysis from the EXAMINE trial

     Article • Diabetes Obesity and Metabolism, March 2021, Wiley

     Dr Joao Pedro Ferreira

175. 
     Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial

     Article • European Journal of Heart Failure, March 2021, Wiley

     Dr Joao Pedro Ferreira

176. 
     Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHESUS, and EXAMINE

     Article • Clinical Research in Cardiology, March 2021, Springer Science + Business Media

     Professor John GF Cleland, Dr Joao Pedro Ferreira

177. 
     Serum potassium and outcomes in heart failure with preserved ejection fraction: a post‐hoc analysis of the PARAGON‐HF trial

     Article • European Journal of Heart Failure, March 2021, Wiley

     Professor John GF Cleland, Dr Joao Pedro Ferreira

178. 
     Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials

     Article • Circulation, March 2021, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

179. 
     Impact of Geographic Region on the COMMANDER-HF Trial

     Article • JACC Heart Failure, March 2021, Elsevier

     Professor John GF Cleland, Dr Joao Pedro Ferreira

180. 
     Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload

     Article • Journal of the American College of Cardiology, March 2021, Elsevier

     Dr Joao Pedro Ferreira

181. 
     Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure

     Article • Journal of the American College of Cardiology, March 2021, Elsevier

     Dr Joao Pedro Ferreira

182. 
     Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: The RA-HF study

     Article • European Journal of Internal Medicine, March 2021, Elsevier

     Dr Joao Pedro Ferreira

183. 
     Head-to-head comparison of clustering methods for heterogeneous data: a simulation-driven benchmark

     Article • Scientific Reports, February 2021, Springer Science + Business Media

     Dr Joao Pedro Ferreira

184. 
     Circulating multimarker approach to identify patients with preclinical left ventricular remodelling and/or diastolic dysfunction

     Article • ESC Heart Failure, February 2021, Wiley

     Dr Joao Pedro Ferreira

185. 
     Impact of Anti-hypertensive Therapy in the Sexual Health of Men and Women: An Analysis From the SPRINT Trial

     Article • American Journal of Hypertension, February 2021, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

186. 
     Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial

     Article • Trials, February 2021, Springer Science + Business Media

     Dr Joao Pedro Ferreira

187. 
     The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future

     Article • The American Journal of Medicine, February 2021, Elsevier

     Dr Joao Pedro Ferreira

188. 
     Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function

     Article • Circulation, January 2021, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

189. 
     Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction

     Article • Circulation, January 2021, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

190. 
     Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status

     Article • Circulation, January 2021, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

191. 
     Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial

     Article • European Heart Journal, January 2021, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

192. 
     Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

     Article • European Heart Journal, January 2021, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

193. 
     Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS‐HFDM) in patients in the ACCORD trial

     Article • Diabetes Obesity and Metabolism, January 2021, Wiley

     Dr Joao Pedro Ferreira

194. 
     Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF

     Article • JACC Heart Failure, January 2021, Elsevier

     Dr Joao Pedro Ferreira

195. 
     Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial

     Article • European Journal of Heart Failure, December 2020, Wiley

     Dr Joao Pedro Ferreira

196. 
     Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure

     Article • European Journal of Heart Failure, December 2020, Wiley

     Dr Joao Pedro Ferreira

197. 
     Estimating the Lifetime Benefits of Treatments for Heart Failure

     Article • JACC Heart Failure, December 2020, Elsevier

     Dr Joao Pedro Ferreira

198. 
     Adverse gastrointestinal events with sodium polystyrene sulphonate and calcium polystyrene sulphonate use in dialysis patients: a nationwide registry study

     Article • Nephrology Dialysis Transplantation, November 2020, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

199. 
     Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial

     Article • Cardiovascular Diabetology, November 2020, Springer Science + Business Media

     Dr Joao Pedro Ferreira

200. 
     Metabolic Syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: A post hoc analyses of the EMPA-REG OUTCOME trial

     Article • November 2020, Springer Science + Business Media

     Dr Joao Pedro Ferreira

201. 
     Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus

     Article • American Heart Journal, November 2020, Elsevier

     Dr Joao Pedro Ferreira

202. 
     Subclinical ventricular dysfunction in rheumatoid arthritis

     Article • The International Journal of Cardiovascular Imaging, October 2020, Springer Science + Business Media

     Dr Joao Pedro Ferreira

203. 
     Plasma D ‐dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER‐HF trial

     Article • European Journal of Heart Failure, October 2020, Wiley

     Professor John GF Cleland, Dr Joao Pedro Ferreira

204. 
     Differences in biomarkers and molecular pathways according to age for patients with HFrEF

     Article • Cardiovascular Research, October 2020, Oxford University Press (OUP)

     Professor John GF Cleland, Dr Joao Pedro Ferreira

205. 
     Serum potassium in the PARADIGM‐HF trial

     Article • European Journal of Heart Failure, September 2020, Wiley

     Dr Joao Pedro Ferreira

206. 
     Metabolic Syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: A post hoc analyses of the EMPA-REG OUTCOME trial

     Article • September 2020, Springer Science + Business Media

     Dr Joao Pedro Ferreira

207. 
     Circulating plasma proteins and new-onset diabetes in a population-based study: proteomic and genomic insights from the STANISLAS cohort

     Article • European Journal of Endocrinology, September 2020, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

208. 
     Reply

     Article • JACC Heart Failure, September 2020, Elsevier

     Dr Joao Pedro Ferreira

209. 
     SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

     Article • The Lancet, September 2020, Elsevier

     Dr Joao Pedro Ferreira

210. 
     Non-fatal cardiovascular events preceding sudden cardiac death in patients with an acute myocardial infarction complicated by heart failure: insights from the high-risk myocardial infarction database

     Article • European Heart Journal Acute Cardiovascular Care, August 2020, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

211. 
     Sex differences in circulating proteins in heart failure with preserved ejection fraction

     Article • Biology of Sex Differences, August 2020, Springer Science + Business Media

     Dr Joao Pedro Ferreira

212. 
     Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial

     Article • Clinical Research in Cardiology, August 2020, Springer Science + Business Media

     Dr Joao Pedro Ferreira

213. 
     Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches

     Article • Heart Failure Reviews, August 2020, Springer Science + Business Media

     Dr Joao Pedro Ferreira

214. 
     Lower socioeconomic status predicts higher mortality and morbidity in patients with heart failure

     Article • Heart, August 2020, BMJ

     Dr Joao Pedro Ferreira

215. 
     Hypokalemia is frequent and has prognostic implications in stable patients attending the emergency department

     Article • PLOS One, August 2020, PLOS

     Dr Joao Pedro Ferreira

216. 
     Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials

     Article • The Lancet, July 2020, Elsevier

     Dr Joao Pedro Ferreira

217. 
     Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT

     Article • European Journal of Heart Failure, June 2020, Wiley

     Dr Joao Pedro Ferreira

218. 
     Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial

     Article • BMC Medicine, June 2020, Springer Science + Business Media

     Dr Joao Pedro Ferreira

219. 
     Abnormalities of Potassium in Heart Failure

     Article • Journal of the American College of Cardiology, June 2020, Elsevier

     Dr Joao Pedro Ferreira

220. 
     Use of the Win Ratio in Cardiovascular Trials

     Article • JACC Heart Failure, June 2020, Elsevier

     Dr Joao Pedro Ferreira

221. 
     Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial

     Article • American Journal of Hypertension, May 2020, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

222. 
     Reduced Diuretic Dose in Patients Treated With Eplerenone

     Article • Circulation Heart Failure, May 2020, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

223. 
     Correlation of laboratory haemoconcentration measures with filling pressures obtained via pulmonary arterial pressure sensors in ambulatory heart failure patients

     Article • European Journal of Heart Failure, April 2020, Wiley

     Dr Joao Pedro Ferreira

224. 
     The intersecting role of glycaemia and cardiac function in the development of heart failure among patients with type 2 diabetes mellitus after an acute coronary syndrome

     Article • European Journal of Heart Failure, April 2020, Wiley

     Dr Joao Pedro Ferreira

225. 
     The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM‐HF and ATMOSPHERE

     Article • European Journal of Heart Failure, April 2020, Wiley

     Dr Joao Pedro Ferreira

226. 
     Health‐related quality of life scores: ending the minimum 5‐point difference as the clinically meaningful threshold

     Article • European Journal of Heart Failure, April 2020, Wiley

     Dr Joao Pedro Ferreira

227. 
     Impact of Uric Acid on Hypertension Occurrence and Target Organ Damage: Insights From the STANISLAS Cohort With a 20-Year Follow-up

     Article • American Journal of Hypertension, April 2020, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

228. 
     Longer Duration of Hypertension and MRI Microvascular Brain Alterations Are Associated with Lower Hippocampal Volumes in Older Individuals with Hypertension

     Article • Journal of Alzheimer’s Disease, March 2020, IOS Press

     Dr Joao Pedro Ferreira

229. 
     Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHESUS trial

     Article • European Heart Journal, March 2020, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

230. 
     Distinct Pathological Pathways in Patients With Heart Failure and Diabetes

     Article • JACC Heart Failure, March 2020, Elsevier

     Dr Joao Pedro Ferreira

231. 
     Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction

     Article • JACC Heart Failure, March 2020, Elsevier

     Dr Joao Pedro Ferreira

232. 
     Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials

     Article • European Journal of Heart Failure, February 2020, Wiley

     Dr Joao Pedro Ferreira

233. 
     Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure)

     Article • Biomarkers, February 2020, Taylor & Francis

     Dr Joao Pedro Ferreira

234. 
     Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study

     Article • Clinical Research in Cardiology, January 2020, Springer Science + Business Media

     Professor John GF Cleland, Dr Joao Pedro Ferreira

235. 
     Biomarkers in patients with heart failure and central sleep apnoea: findings from the SERVE‐HF trial

     Article • ESC Heart Failure, January 2020, Wiley

     Dr Joao Pedro Ferreira

236. 
     Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof‐of‐concept, randomised, precision‐medicine, prevention trial. The Heart OMics in AGing ...

     Article • European Journal of Heart Failure, January 2020, Wiley

     Dr Pierpaolo Pellicori, Professor John GF Cleland, Dr Joao Pedro Ferreira

237. 
     Predictors of sudden cardiac death in high‐risk patients following a myocardial infarction

     Article • European Journal of Heart Failure, January 2020, Wiley

     Dr Joao Pedro Ferreira

238. 
     Body fat phenotypes and treatment response to spironolactone in ambulatory patients with heart failure and preserved ejection fraction: a post‐hoc analysis of the Aldo‐DHF trial

     Article • European Journal of Heart Failure, January 2020, Wiley

     Dr Joao Pedro Ferreira

239. 
     Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial

     Article • Journal of the American Heart Association, January 2020, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

240. 
     OUP accepted manuscript

     Article • European Heart Journal, January 2020, Oxford University Press (OUP)

     Dr Pierpaolo Pellicori, Professor John GF Cleland, Dr Joao Pedro Ferreira

241. 
     Heritability of a resting heart rate in a 20-year follow-up family cohort with GWAS data: Insights from the STANISLAS cohort

     Article • European Journal of Preventive Cardiology, December 2019, SAGE Publications

     Dr Joao Pedro Ferreira

242. 
     Cardiovascular and non‐cardiovascular death distinction: the utility of troponin beyond N‐terminal pro‐B‐type natriuretic peptide. Findings from the BIOSTAT‐CHF study

     Article • European Journal of Heart Failure, December 2019, Wiley

     Dr Joao Pedro Ferreira, Professor John GF Cleland

243. 
     Income level and inequality as complement to geographical differences in cardiovascular trials

     Article • American Heart Journal, December 2019, Elsevier

     Dr Joao Pedro Ferreira

244. 
     MRAs in Elderly HF Patients

     Article • JACC Heart Failure, December 2019, Elsevier

     Dr Joao Pedro Ferreira

245. 
     Bioprofiles and mechanistic pathways associated with Cheyne-Stokes respiration: insights from the SERVE-HF trial

     Article • Clinical Research in Cardiology, November 2019, Springer Science + Business Media

     Dr Joao Pedro Ferreira

246. 
     Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF

     Article • European Journal of Internal Medicine, November 2019, Elsevier

     Dr Joao Pedro Ferreira, Professor John GF Cleland

247. 
     Renin-angiotensin-aldosterone system and kidney interactions in heart failure

     Article • Journal of the Renin-Angiotensin-Aldosterone System, October 2019, SAGE Publications

     Dr Joao Pedro Ferreira

248. 
     Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction

     Article • Journal of Hypertension, October 2019, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

249. 
     Eplerenone in patients with myocardial infarction and “mid‐range” ejection fraction: An analysis from the EPHESUS trial

     Article • Clinical Cardiology, September 2019, Wiley

     Dr Joao Pedro Ferreira

250. 
     World Heart Federation Roadmap for Heart Failure

     Article • Global Heart, September 2019, Elsevier

     Dr Joao Pedro Ferreira

251. 
     Heart failure around the world

     Article • European Journal of Heart Failure, August 2019, Wiley

     Dr Joao Pedro Ferreira

252. 
     Mid-term prognostic impact of residual pulmonary congestion assessed by radiographic scoring in patients admitted for worsening heart failure

     Article • International Journal of Cardiology, August 2019, Elsevier

     Dr Joao Pedro Ferreira

253. 
     External Validation of the ELAN‐HF Score, Predicting 6‐Month All‐Cause Mortality in Patients Hospitalized for Acute Decompensated Heart Failure

     Article • Journal of the American Heart Association, July 2019, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

254. 
     Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with A...

     Article • Clinical Research in Cardiology, June 2019, Springer Science + Business Media

     Dr Joao Pedro Ferreira

255. 
     A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial

     Article • European Heart Journal, June 2019, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira, Professor John GF Cleland

256. 
     Chest X-ray quantification of admission lung congestion as a prognostic factor in patients admitted for worsening heart failure from the ICALOR cohort study

     Article • International Journal of Cardiology, June 2019, Elsevier

     Dr Joao Pedro Ferreira

257. 
     Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS case–control analyses

     Article • Clinical Research in Cardiology, May 2019, Springer Science + Business Media

     Dr Joao Pedro Ferreira

258. 
     Estimated Long-Term Survival With Eplerenone

     Article • Journal of the American College of Cardiology, May 2019, Elsevier

     Dr Joao Pedro Ferreira

259. 
     Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure

     Article • Circulation Heart Failure, May 2019, Wolters Kluwer Health

     Dr Joao Pedro Ferreira, Professor John GF Cleland

260. 
     Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative

     Article • Clinical Research in Cardiology, April 2019, Springer Science + Business Media

     Dr Joao Pedro Ferreira

261. 
     Income Inequality and Outcomes in Heart Failure

     Article • JACC Heart Failure, April 2019, Elsevier

     Dr Joao Pedro Ferreira, Professor Vladimir V Rafalskiy

262. 
     Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS‐HF trial

     Article • European Journal of Heart Failure, February 2019, Wiley

     Dr Joao Pedro Ferreira

263. 
     Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline

     Article • European Journal of Heart Failure, February 2019, Wiley

     Dr Joao Pedro Ferreira

264. 
     Nondipping Pattern and Cardiovascular and Renal Damage in a Population-Based Study (The STANISLAS Cohort Study)

     Article • American Journal of Hypertension, February 2019, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

265. 
     Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments

     Article • European Heart Journal Supplements, February 2019, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

266. 
     Is Sacubitril/Valsartan Antifibrotic?

     Article • Journal of the American College of Cardiology, February 2019, Elsevier

     Dr Joao Pedro Ferreira

267. 
     Balancing Benefits and Risks of Spironolactone in HFpEF and Chronic Kidney Disease Patients

     Article • JACC Heart Failure, January 2019, Elsevier

     Dr Joao Pedro Ferreira

268. 
     Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study

     Article • European Journal of Heart Failure, January 2019, Wiley

     Dr Joao Pedro Ferreira, Professor John GF Cleland

269. 
     Extracting Meaning of Tubular Injury Molecules: Implications for Cardiorenal Health

     Article • American Journal of Nephrology, January 2019, Karger Publishers

     Dr Joao Pedro Ferreira

270. 
     Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study

     Article • Nephrology Dialysis Transplantation, December 2018, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

271. 
     Echocardiographic diastolic function evolution in patients with an anterior Q-wave myocardial infarction: insights from the REVE-2 study

     Article • ESC Heart Failure, November 2018, Wiley

     Dr Joao Pedro Ferreira

272. 
     Correction to: Prognostic value of estimated plasma volume in acute heart failure in three cohort studies

     Article • Clinical Research in Cardiology, November 2018, Springer Science + Business Media

     Dr Joao Pedro Ferreira

273. 
     Survival after bilateral internal mammary artery in coronary artery bypass grafting: Are women at risk?

     Article • International Journal of Cardiology, November 2018, Elsevier

     Dr Joao Pedro Ferreira

274. 
     Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study

     Article • European Journal of Heart Failure, October 2018, Wiley

     Dr Joao Pedro Ferreira

275. 
     Prognostic value of estimated plasma volume in acute heart failure in three cohort studies

     Article • Clinical Research in Cardiology, October 2018, Springer Science + Business Media

     Dr Joao Pedro Ferreira

276. 
     Patient-reported and morbidity-mortality endpoints: can one have the best of both worlds?

     Article • European Journal of Heart Failure, October 2018, Wiley

     Dr Joao Pedro Ferreira

277. 
     Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus

     Article • JACC Heart Failure, October 2018, Elsevier

     Dr Joao Pedro Ferreira

278. 
     Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points

     Article • Circulation Cardiovascular Quality and Outcomes, October 2018, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

279. 
     Editor’s Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction

     Article • European Heart Journal Acute Cardiovascular Care, September 2018, SAGE Publications

     Professor Faiez zannad, Dr Joao Pedro Ferreira

280. 
     Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial

     Article • Clinical Research in Cardiology, September 2018, Springer Science + Business Media

     Dr Joao Pedro Ferreira

281. 
     Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials

     Article • Clinical Research in Cardiology, September 2018, Springer Science + Business Media

     Dr Joao Pedro Ferreira

282. 
     Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure

     Article • Heart, August 2018, BMJ

     Dr Joao Pedro Ferreira, Professor John GF Cleland

283. 
     Visit-to-visit blood pressure variation is associated with outcomes in a U-shaped fashion in patients with myocardial infarction complicated with systolic dysfunction and/or heart failure

     Article • Journal of Hypertension, August 2018, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

284. 
     Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns

     Article • Circulation Heart Failure, July 2018, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

285. 
     Association between abdominal adiposity and 20-year subsequent aortic stiffness in an initially healthy population-based cohort

     Article • Journal of Hypertension, June 2018, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

286. 
     Fibrosis mechanistic phenotyping and antifibrotic response determination with biomarkers in heart failure: one single biomarker may not fit all settings

     Article • European Journal of Heart Failure, May 2018, Wiley

     Dr Joao Pedro Ferreira

287. 
     Obesity and metabolic features associated with long-term developing diastolic dysfunction in an initially healthy population-based cohort

     Article • Clinical Research in Cardiology, April 2018, Springer Science + Business Media

     Dr Joao Pedro Ferreira

288. 
     Relation of High Serum Bilirubin to Short-Term Mortality Following a Myocardial Infarction Complicated by Left Ventricular Systolic Dysfunction (From the High-Risk Myocardial Infarction Database Initiative)

     Article • The American Journal of Cardiology, February 2018, Elsevier

     Dr Joao Pedro Ferreira

289. 
     Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation

     Article • Journal of the American College of Cardiology, February 2018, Elsevier

     Dr Joao Pedro Ferreira

290. 
     Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction

     Article • European Journal of Heart Failure, January 2018, Wiley

     Dr Joao Pedro Ferreira

291. 
     NT-proBNP-Guided Therapy in Acute Decompensated Heart Failure: The PRIMA II Randomized Controlled Trial

     Article • Circulation, December 2017, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

292. 
     Cohort Profile: Rationale and design of the fourth visit of the STANISLAS Cohort: a familial longitudinal population-based cohort from the Nancy region of France

     Article • International Journal of Epidemiology, December 2017, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

293. 
     Interpretation of the ATHENA Trial—Caveats and Future Directions

     Article • JAMA Cardiology, December 2017, American Medical Association (AMA)

     Dr Joao Pedro Ferreira

294. 
     Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis

     Article • ESC Heart Failure, October 2017, Wiley

     Dr Joao Pedro Ferreira, Professor Javier Diez

295. 
     Practical management of concomitant acute heart failure and worsening renal function in the emergency department

     Article • European Journal of Emergency Medicine, October 2017, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

296. 
     The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure

     Article • Journal of the American College of Cardiology, October 2017, Elsevier

     Dr Joao Pedro Ferreira

297. 
     Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study

     Article • Clinical Research in Cardiology, August 2017, Springer Science + Business Media

     Dr Joao Pedro Ferreira

298. 
     Coronary angiography in worsening heart failure: determinants, findings and prognostic implications

     Article • Heart, August 2017, BMJ

     Dr Joao Pedro Ferreira, Professor John GF Cleland

299. 
     Individualizing treatment choices in the systolic blood pressure intervention trial

     Article • Journal of Hypertension, August 2017, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

300. 
     Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF

     Article • European Journal of Heart Failure, June 2017, Wiley

     Dr Joao Pedro Ferreira

301. 
     Risk for Incident Heart Failure: A Subject‐Level Meta‐Analysis From the Heart “OMics” in AGEing (HOMAGE) Study

     Article • Journal of the American Heart Association, May 2017, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

302. 
     Reply

     Article • Journal of the American College of Cardiology, May 2017, Elsevier

     Dr Joao Pedro Ferreira

303. 
     Hyperkalaemia prevalence, recurrence and management in chronic haemodialysis: a prospective multicentre French regional registry 2-year survey

     Article • Nephrology Dialysis Transplantation, April 2017, Oxford University Press (OUP)

     Dr Joao Pedro Ferreira

304. 
     Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?

     Article • European Journal of Heart Failure, April 2017, Wiley

     Dr Joao Pedro Ferreira

305. 
     Memory Alterations and White Matter Hyperintensities in Elderly Patients With Hypertension: The ADELAHYDE-2 Study

     Article • Journal of the American Medical Directors Association, March 2017, Elsevier

     Dr Joao Pedro Ferreira

306. 
     Serum Chloride and Sodium Interplay in Patients With Acute Myocardial Infarction and Heart Failure With Reduced Ejection FractionCLINICAL PERSPECTIVE

     Article • Circulation Heart Failure, February 2017, Wolters Kluwer Health

     Dr Joao Pedro Ferreira, Professor john j mcmurray

307. 
     Lack of Diuretic Efficiency (but Not Low Diuresis) Early in An Acutely Decompensated Heart Failure Episode Is Associated with Increased 180-Day Mortality

     Article • Cardiorenal Medicine, January 2017, Karger Publishers

     Dr Joao Pedro Ferreira

308. 
     High Pulse-Wave Velocity Defines a Very High Cardiovascular Risk Cohort of Dialysis Patients under Age 60

     Article • American Journal of Nephrology, November 2016, Karger Publishers

     Dr Joao Pedro Ferreira

309. 
     Oral Anticoagulant Agents in Patients With Atrial Fibrillation and Heart Failure

     Article • JACC Heart Failure, November 2016, Elsevier

     Dr Joao Pedro Ferreira

310. 
     Association of beta‐blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched‐cohort analysis from the High‐Risk Myoca...

     Article • European Journal of Heart Failure, October 2016, Wiley

     Dr Joao Pedro Ferreira

311. 
     A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis

     Article • European Journal of Heart Failure, September 2016, Wiley

     Dr Joao Pedro Ferreira

312. 
     Intima–Media Thickness Is Linearly and Continuously Associated With Systolic Blood Pressure in a Population‐Based Cohort (STANISLAS Cohort Study)

     Article • Journal of the American Heart Association, June 2016, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

313. 
     Enlarging Red Blood Cell Distribution Width During Hospitalization Identifies a Very High-Risk Subset of Acutely Decompensated Heart Failure Patients and Adds Valuable Prognostic Information on Top of Hemoconcentration

     Article • Medicine, April 2016, Wolters Kluwer Health

     Dr Joao Pedro Ferreira

314. 
     Predictors and prognostic significance of tachycardiomyopathy: insights from a cohort of 1269 patients undergoing atrial flutter ablation

     Article • European Journal of Heart Failure, February 2016, Wiley

     Dr Béatrice Brembilla-Perrot, Dr Joao Pedro Ferreira

315. 
     Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect

     Article • Clinical Research in Cardiology, November 2015, Springer Science + Business Media

     Dr Joao Pedro Ferreira

316. 
     To the Editor— Diabetes and sudden death: Let’s assess the absolute risk increase rather than the proportional risk from sudden cardiac death!

     Article • Heart Rhythm, November 2015, Elsevier

     Dr Joao Pedro Ferreira

317. 
     A Systematic Assessment of Absolute Treatment Effect

     Article • The American Journal of Cardiology, September 2015, Elsevier

     Dr Joao Pedro Ferreira

318. 
     Geographic differences in heart failure trials

     Article • European Journal of Heart Failure, July 2015, Wiley

     Dr Joao Pedro Ferreira

319. 
     Oxygen therapy: a clinical audit in an Internal Medicine Department

     Article • Revista Portuguesa de Pneumologia (English Edition), March 2015, Elsevier

     Dr Joao Pedro Ferreira

320. 
     Heart Failure and Atrial Fibrillation: From Basic Science to Clinical Practice

     Article • International Journal of Molecular Sciences, January 2015, MDPI AG

     Dr Joao Pedro Ferreira

321. 
     High-dose spironolactone changes renin and aldosterone levels in acutely decompensated heart failure

     Article • Cor et Vasa, December 2014, Elsevier

     Dr Joao Pedro Ferreira

322. 
     The role of albuminuria as a non-invasive marker for congestive acutely decompensated chronic heart failure and the spironolactone effect in elderly Portuguese: a non-randomized trial

     Article • Nephrology, February 2014, Wiley

     Dr Joao Pedro Ferreira

323. 
     Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure

     Article • European Journal of Internal Medicine, January 2014, Elsevier

     Dr Joao Pedro Ferreira

324. 
     High-Sensitivity Troponin T: A Biomarker for Diuretic Response in Decompensated Heart Failure Patients

     Article • Cardiology Research and Practice, January 2014, Hindawi Publishing Corporation

     Dr Joao Pedro Ferreira

325. 
     Influence of Spironolactone on Matrix Metalloproteinase-2 in Acute Decompensated Heart Failure

     Article • Arquivos Brasileiros de Cardiologia, January 2014, GN1 Genesis Network

     Dr Joao Pedro Ferreira

326. 
     Left-sided infective endocarditis: Analysis of in-hospital and medium-term outcome and predictors of mortality

     Article • Revista Portuguesa de Cardiologia, October 2013, Elsevier

     Dr Joao Pedro Ferreira

327. 
     Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors

     Article • Clinical Research in Cardiology, July 2013, Springer Science + Business Media

     Dr Joao Pedro Ferreira

328. 
     Anti-Ro52 Antibodies and Interstitial Lung Disease in Connective Tissue Diseases Excluding Scleroderma

     Article • ISRN Rheumatology, January 2012, Hindawi Publishing Corporation

     Dr Joao Pedro Ferreira

329. 
     Investigating a Case of Recurrent Pleural Effusion

     Article • Case Reports in Pulmonology, January 2011, Hindawi Publishing Corporation

     Dr Joao Pedro Ferreira